Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Medtronic (MDT) -- Ignore unavailable to you. Want to Upgrade?

To: Mike who wrote (473)	3/29/2000 3:38:00 PM
From: Mike	Read Replies (1) \| Respond to of 687

From another board. Mike To: Howard who wrote (731) From: Lighthouse Tuesday, Mar 28, 2000 9:38 PM ET Reply # of 732 Perhaps a little, but I have only one source on this. A report is out that Guidant is about to settle with JNJ over the 'basic' stent patnets that JNJ holds. Included in the rumored deal is a part of Biosense that JNJ owns. The number I read for the settlement was $400,000,000 and that included the Biosense piece. The number is larger than I expected and puts pressure on MDT and BSX to settle the case as well or risk a trial. We shall see if this information holds up. I am merely a relay on this one folks, trust your own due diligence and do not believe every 'rumor' some idiot like me posts on this board. Cheers,

To: Mike who wrote (473)	3/29/2000 7:56:00 PM
From: Mike	Respond to of 687

From Yahoo. Mike R/X S670 patent by: mhattrik98 3/29/00 7:52 pm Msg: 5660 of 5660 MDT has a patent on the rapid exchange catheter from the Bard purchase (I think). But the point is they do have a patent on a rapid exchange system. From what I have gathered it is only with a perfusion balloon. The R/X S670 is a perfusion balloon but the question is, is 5cc of perfusion enough? Can anyone address this issue? Mhat